CLU and liver disorder: These results provide compelling evidence that decreasing NLRP3 activity by upregulating clusterin can effectively reduce the inflammatory response in HCs and confirm the therapeutic potential of modulating this pathway in liver diseases associated with increased inflammasome activity.